A Study to Assess New Formulations of TEV-56286

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

June 2, 2025

Study Completion Date

June 2, 2025

Conditions

Healthy Participants

Interventions

DRUG

TEV-56286 Test

Administered orally

DRUG

TEV-56286 Reference

Administered orally

Trial Locations (1)

Teva Investigational Site 12141, Miramar

All Listed Sponsors

lead

Teva Branded Pharmaceutical Products R&D LLC

INDUSTRY

NCT06911567 - A Study to Assess New Formulations of TEV-56286 | Biotech Hunter | Biotech Hunter